Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can A REMS Save Raptiva? Tysabri-Style Program Would Mean Restrictions

Executive Summary

Ongoing discussions about a risk management plan for Genentech's Raptiva (efalizumab) may provide an avenue to maintain the psoriasis drug's commercial viability, despite its safety problems
Advertisement

Related Content

Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA
Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA
Genentech Aborts Raptiva Amidst Reports Of Fatal Brain Infection
Good News, Bad News For Novartis’ Oral MS Drug, But REMS Could Help
Raptiva PML Case Brings Another REMS
PML Reported In Raptiva User; Genentech Sends “Dear Doctor” Letter
Patient In New Rituxan PML Case Had “Complex” History
Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive

Topics

Advertisement
UsernamePublicRestriction

Register

PS050708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel